
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific's overall performance is marked by significant growth in critical segments, as evidenced by a 35% year-over-year increase in Watchman sales and a robust 63% growth in electrophysiology (EP) products, indicating strong market demand and share acquisition. The company is projecting organic sales growth of 11-13% for the upcoming quarter, alongside a solid earnings outlook, with GAAP EPS anticipated between $0.48 and $0.52. Additionally, strategic innovations like the Nalu device, along with the ongoing expansion of its interventional oncology and imaging portfolios, are expected to sustain high growth rates, further enhancing the company's financial prospects.
Bears say
Boston Scientific's outlook is negatively impacted by an expected foreign exchange headwind of approximately $0.04 to adjusted earnings for the full year, alongside a revenue forecast indicating only slight growth relative to previous estimates. The firm operates in mature markets with significant exposure to competitive pricing pressures in its Cardiac Rhythm Management (CRM) and Drug-Eluting Stents (DES) portfolios, which could constrain future growth. Additionally, challenges in the integration of newly acquired companies and the underperformance of key franchises, such as urology, may hinder Boston Scientific's ability to meet internal projections and market consensus.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares